市場調査レポート

商品コード

1499968

神経調節の世界市場の評価：タイプ別、用途別、生体材料別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Neuromodulation Market Assessment, By Type, By Application, By Biomaterial, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年06月25日
発行: Markets & Data
ページ情報: 英文 234 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,800 706,032円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 6,000 882,540円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,500 1,250,265円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.09円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の神経調節の市場規模は、2024年～2031年の予測期間中に10.28％のCAGRで拡大し、2023年の52億3,000万米ドルから2031年には114億4,000万米ドルに成長すると予測されています。同市場の成長を後押ししているのは、パーキンソン病、てんかん、慢性疼痛、片頭痛など、さまざまな慢性神経疾患の有病率の上昇、高度な神経調節技術の開発重視の高まり、神経調節療法のさまざまな利点に関する認知度の向上です。

さまざまな神経疾患の有病率の上昇は、世界の神経調節市場の主要動向です。中でも慢性疼痛に悩む人の増加率は、神経調節療法や機器の需要を高める主な要因の1つです。米国疼痛財団（US Pain Foundation）の推計によると、米国人口の約21％に当たる約5,160万人の成人が慢性疼痛を抱えており、疼痛管理や治療に役立つ神経調節デバイスの需要が高まっています。植え込み型神経調節装置を使用すると、多裂筋に継続的な収縮を与えることで脊椎の強度と安定性が再確立され、痛みが軽減されます。

患者の快適性と利便性を高めるため、先進的で斬新な治療ソリューションの導入に向けた様々な市場参入企業の取り組みが活発化していることは、世界の神経調節市場規模を押し上げる主な要因の一つです。

当レポートでは、世界の神経調節市場について調査し、市場の概要とともに、タイプ別、用途別、生体材料別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 4. Global Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 5. Global Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 6. Global Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 7. Global Neuromodulation Market Share (%), By Region, 2017-2031F
Figure 8. North America Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 9. North America Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 10. North America Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 11. North America Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 12. North America Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 13. North America Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 14. North America Neuromodulation Market Share (%), By Country, 2017-2031F
Figure 15. United States Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 16. United States Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 17. United States Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 18. United States Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 19. United States Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 20. United States Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 21. Canada Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 22. Canada Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 23. Canada Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 24. Canada Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 25. Canada Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 26. Canada Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 27. Mexico Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 28. Mexico Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 29. Mexico Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 30. Mexico Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 31. Mexico Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 32. Mexico Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 33. Europe Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 34. Europe Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 35. Europe Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 36. Europe Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 37. Europe Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 38. Europe Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 39. Europe Neuromodulation Market Share (%), By Country, 2017-2031F
Figure 40. Germany Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 41. Germany Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 42. Germany Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 43. Germany Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 44. Germany Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 45. Germany Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 46. France Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 47. France Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 48. France Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 49. France Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 50. France Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 51. France Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 52. Italy Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 53. Italy Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 54. Italy Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 55. Italy Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 56. Italy Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 57. Italy Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 58. United Kingdom Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 59. United Kingdom Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 60. United Kingdom Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 61. United Kingdom Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 62. United Kingdom Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 63. United Kingdom Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 64. Russia Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 65. Russia Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 66. Russia Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 67. Russia Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 68. Russia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 69. Russia Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 70. Netherlands Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 71. Netherlands Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 72. Netherlands Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 73. Netherlands Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 74. Netherlands Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 75. Netherlands Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 76. Spain Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 77. Spain Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 78. Spain Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 79. Spain Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 80. Spain Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 81. Spain Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 82. Turkey Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 83. Turkey Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 84. Turkey Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 85. Turkey Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 86. Turkey Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 87. Turkey Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 88. Poland Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 89. Poland Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 90. Poland Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 91. Poland Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 92. Poland Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 93. Poland Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 94. South America Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 95. South America Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 96. South America Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 97. South America Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 98. South America Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 99. South America Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 100. South America Neuromodulation Market Share (%), By Country, 2017-2031F
Figure 101. Brazil Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 102. Brazil Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 103. Brazil Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 104. Brazil Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 105. Brazil Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 106. Brazil Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 107. Argentina Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 108. Argentina Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 109. Argentina Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 110. Argentina Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 111. Argentina Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 112. Argentina Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 113. Asia-Pacific Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 114. Asia-Pacific Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 115. Asia-Pacific Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 116. Asia-Pacific Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 117. Asia-Pacific Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 118. Asia-Pacific Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 119. Asia-Pacific Neuromodulation Market Share (%), By Country, 2017-2031F
Figure 120. India Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 121. India Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 122. India Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 123. India Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 124. India Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 125. India Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 126. China Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 127. China Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 128. China Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 129. China Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 130. China Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 131. China Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 132. Japan Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 133. Japan Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 134. Japan Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 135. Japan Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 136. Japan Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 137. Japan Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 138. Australia Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 139. Australia Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 140. Australia Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 141. Australia Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 142. Australia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 143. Australia Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 144. Vietnam Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 145. Vietnam Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 146. Vietnam Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 147. Vietnam Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 148. Vietnam Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 149. Vietnam Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 150. South Korea Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 151. South Korea Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 152. South Korea Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 153. South Korea Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 154. South Korea Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 155. South Korea Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 156. Indonesia Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 157. Indonesia Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 158. Indonesia Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 159. Indonesia Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 160. Indonesia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 161. Indonesia Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 162. Philippines Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 163. Philippines Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 164. Philippines Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 165. Philippines Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 166. Philippines Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 167. Philippines Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 168. Middle East & Africa Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 169. Middle East & Africa Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 170. Middle East & Africa Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 171. Middle East & Africa Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 172. Middle East & Africa Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 173. Middle East & Africa Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 174. Middle East & Africa Neuromodulation Market Share (%), By Country, 2017-2031F
Figure 175. Saudi Arabia Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 176. Saudi Arabia Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 177. Saudi Arabia Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 178. Saudi Arabia Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 179. Saudi Arabia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 180. Saudi Arabia Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 181. UAE Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 182. UAE Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 183. UAE Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 184. UAE Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 185. UAE Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 186. UAE Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 187. South Africa Neuromodulation Market, By Value, In USD Billion, 2017-2031F
Figure 188. South Africa Neuromodulation Market, By Volume, In Million Units, 2017-2031F
Figure 189. South Africa Neuromodulation Market Share (%), By Type, 2017-2031F
Figure 190. South Africa Neuromodulation Market Share (%), By Application, 2017-2031F
Figure 191. South Africa Neuromodulation Market Share (%), By Biomaterial, 2017-2031F
Figure 192. South Africa Neuromodulation Market Share (%), By End-user, 2017-2031F
Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195. By Biomaterial Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11506

Global neuromodulation market is projected to witness a CAGR of 10.28% during the forecast period 2024-2031F, growing from USD 5.23 billion in 2023 to USD 11.44 billion in 2031F. The market's growth is boosted by the increasing prevalence of various chronic neurological conditions, including Parkinson's Disease, epilepsy, chronic pain, migraine, and others, rising emphasis on developing advanced neuromodulation technologies and increasing awareness about various advantages of neuromodulation therapies.

The increasing prevalence of different neurological conditions is a major global neuromodulation market trend. The rising incidence of individuals suffering from chronic pain, among others, is one of the major factors bolstering the demand for neuromodulation therapies and devices. According to the estimates of the US Pain Foundation, approximately 51.6 million adults, almost 21% of the population of the United States, are living with chronic pain, propelling the requirement for neuromodulation devices as they aid in pain management and treatment of the condition. Using implanted restorative neuromodulation devices re-establishes the strength and stability of the spine by providing continuous contractions to the multifidus muscles, resulting in reduced pain.

The growing efforts by various market players towards introducing advanced and novel therapeutic solutions to enhance patient comfort and convenience is one of the major factors boosting the global neuromodulation market size. For instance, in March 2024, Axonics announced that their Axonics R20 rechargeable sacral neuromodulation (SNM) system received CE-mark approval. The R20 provides patients and physicians with expanded magnetic resonance imaging (MRI) labeling and enhanced programming capabilities. R20 underscores Axonics' commitment to innovation and provides a significant breakthrough for rechargeable neuromodulation devices.

Such efforts allow the development of neuromodulation devices that support the treatment of diseases and disorders for which neuromodulation was not previously used. In March 2023, GreyMatters's Prism technology became the first neuromodulation system to receive approval from the Food and Drug Administration (FDA) as an adjunct PTSD treatment. GrayMatters aims to use deidentified data collected throughout Prism treatments to develop patient management tools and treatment predictors.

Research and Development Activities Support Global Neuromodulation Market Growth

The growing efforts by various organizations and companies towards research and development activities are expected to support the market expansion in the coming years. Such efforts bolster the development of advanced technologies and products, which are then approved for use by suitable regulatory bodies. For instance, in January 2024, Neurolief's Relivion received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) as a migraine therapy in Japan. The device uses multi-channel and non-invasive brain neuromodulation technology and stimulates both trigeminal and occipital nerve branches, neural pathways that are responsible for migraine. RelivionMG, which is used for treating acute migraines, received approval from the U.S. FDA.

Research and development activities enhance patient convenience and aid in developing high-quality products to ensure better patient outcomes. They allow the translation of ideas, aiding healthcare professionals in addressing the different requirements of their patients and making therapies and products accessible, affordable, and acceptable. Due to the growing burden of different neurological conditions, including migraine and Parkinson's, the investments in research and development activities are increasing, thus bolstering product innovation and positively influencing the expansion of the market.

Increasing Prevalence of Neurological Conditions Boosts Global Neuromodulation Market Demand

According to the estimates of the World Health Organization (WHO), more than 50 million people across the globe are living with epilepsy, which is one of the most common neurological diseases. The approved neuromodulation therapies for treating adults with drug-resistant focal epilepsy include responsive neurostimulation, deep brain stimulation of the anterior nucleus of the thalamus, and vagus nerve stimulation.

The rising number of different neurological conditions such as migraine, epilepsy, and chronic pain, coupled with increasing awareness and rate of diagnosis, is propelling the requirement for neuromodulation devices across the globe. This is because treating several disorders relies upon creating focal points or biological and chronic noncurative pharmacologic treatments. The broad therapeutic potential of neuromodulation and ongoing improvements in biotechnology are providing lucrative growth opportunities to the market. Moreover, neuromodulation devices are capable of stimulating responses in conditions where previously they weren't available, including the cochlear implant, which is used to restore hearing for deaf patients. Thus, as the prevalence of different neurological conditions increases, the demand for neuromodulation devices is expected to rise, supporting the expansion of the market.

North America to Account for Significant Global Neuromodulation Market Share

The strong presence of several leading market players, rising emphasis on developing novel therapeutics solutions, and growing requirement for neuromodulation devices due to the increasing prevalence of neurological disorders are major factors augmenting the market growth in North America. The rising investments by leading market players in research and development activities provide lucrative growth opportunities for the market as these activities support the innovation of products with advanced technologies.

As per the estimates of the American Migraine Foundation, approximately 39 million Americans are living with migraine. Due to the rising prevalence of such conditions, the requirement for different treatment solutions is increasing, including neuromodulation devices. The high rate of adoption of advanced and novel technologies in the region, coupled with increased investments in the biopharmaceutical and pharmaceutical sectors, is further propelling the growth of the market.

Parkinson's Disease Accounts for Significant Global Neuromodulation Market Share

The increasing prevalence of Parkinson's disease in various regions across the globe is providing lucrative growth opportunities to the market. According to the estimates of the Parkinson's Foundation, approximately 90,000 individuals are diagnosed with Parkinson's disease every year in the United States. Parkinson's disease is characterized by various motor symptoms such as postural instability, rigidity, tremors, and bradykinesia. The physiological dysfunction of the condition involves basal ganglia pathways that contribute towards non-motor and motor symptoms, the pathways can be influenced by neural network modulations with the help of magnetic or electrical fields. Deep brain stimulation is often used for treating the condition by applying small pulses of electrical currents at various locations in the brain using implanted electrodes. The stimulations then aid in restoring the circuit balance that had been disrupted by the condition. They alleviate tremors and reduce dyskinesias and stiffness and are highly effective against on and off fluctuations. Thus, bolstering the demand for neuromodulation devices. Additionally, rising efforts towards the development of noninvasive neuromodulation technologies as potential treatments for Parkinson's disease is expected to provide lucrative growth opportunities to the market in the coming years.

Future Market Scenario (2024 - 2031F)

According to the global neuromodulation market analysis, the market is expected to grow significantly over the forecast period. The growth will be supported by the increase in the number of cases of various neurological diseases such as migraine, rising collaborations between the key players of the market, and growing investments towards research activities by various research institutions across the globe. For instance, the University of Calgary is conducting an interventional study to assess the working of a novel neuromodulation device for acute migraine attacks in children and adolescents. The randomized clinical trial aims to determine the acceptability and feasibility of implementing phase III RCT for treating adolescents and children suffering from acute migraine attacks. The study aims to gather preliminary safety and efficacy data on the utilization of REN and is expected to conclude in August 2024.

Over the coming years, the advancements in the understanding of mechanism of action of stimulation and neuroanatomical networks along with advancements in miniaturization and material sciences will bolster the utilization of neuromodulation devices. The future modulation methods are expected to aim for reduced invasiveness and high specificity.

Key Players Landscape and Outlook

The growth of the market is supported by successful mergers and collaborations and acquisitions that allow companies to expand their customer base and enhance their product portfolio. In September 2023, Boston Scientific Corporation announced that they had successfully acquired Relievant Medsystems, Inc., the medical technology company known for commercializing and developing the Intracept Intraosseous Nerve Ablation System for treating vertebrogenic pain. Relievant Medsystems is expected to witness year over year growth that exceeds 50% in 2024. The acquisition intends to support the expansion of the neuromodulation portfolio of Boston Scientific, allowing them to provide more treatment solutions for patients living with chronic back pain.

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Neuromodulation Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2. By Type
- 4.2.1. External Neuromodulation
  - 4.2.1.1. Transcranial Magnetic Stimulator
  - 4.2.1.2. Respiratory Electrical Stimulator
  - 4.2.1.3. Transcutaneous Electrical Nerve Stimulator
- 4.2.2. Internal Neuromodulation
  - 4.2.2.1. Spinal Cord Stimulator
  - 4.2.2.2. Vagus Nerve Stimulator
  - 4.2.2.3. Gastric Electrical Stimulator
  - 4.2.2.4. Deep Brain Stimulator
  - 4.2.2.5. Sacral Nerve Stimulator
4.3. By Application
- 4.3.1. Parkinson's Disease
- 4.3.2. Failed Back Syndrome
- 4.3.3. Tremor
- 4.3.4. Depression
- 4.3.5. Urinary and Fecal Incontinence
- 4.3.6. Chronic Pain Management
- 4.3.7. Dystonia
- 4.3.8. Migraine
- 4.3.9. Epilepsy
- 4.3.10. Others
4.4. By Biomaterial
- 4.4.1. Polymeric Biomaterials
- 4.4.2. Metallic Biomaterials
- 4.4.3. Ceramic Biomaterials
4.5. By End-user
- 4.5.1. Hospitals
- 4.5.2. Specialty Clinics
- 4.5.3. Others
4.6. By Region
- 4.6.1. North America
- 4.6.2. South America
- 4.6.3. Europe
- 4.6.4. Asia-Pacific
- 4.6.5. Middle East and Africa
4.7. By Company Market Share (%), 2023

5. Global Neuromodulation Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. By Value
  - 5.1.1.2. By Volume
- 5.1.2. By Type
  - 5.1.2.1. External Neuromodulation
    - 5.1.2.1.1. Transcranial Magnetic Stimulator
    - 5.1.2.1.2. Respiratory Electrical Stimulator
    - 5.1.2.1.3. Transcutaneous Electrical Nerve Stimulator
  - 5.1.2.2. Internal Neuromodulation
    - 5.1.2.2.1. Spinal Cord Stimulator
    - 5.1.2.2.2. Vagus Nerve Stimulator
    - 5.1.2.2.3. Gastric Electrical Stimulator
    - 5.1.2.2.4. Deep Brain Stimulator
    - 5.1.2.2.5. Sacral Nerve Stimulator
- 5.1.3. By Application
  - 5.1.3.1. Parkinson's Disease
  - 5.1.3.2. Failed Back Syndrome
  - 5.1.3.3. Tremor
  - 5.1.3.4. Depression
  - 5.1.3.5. Urinary and Fecal Incontinence
  - 5.1.3.6. Chronic Pain Management
  - 5.1.3.7. Dystonia
  - 5.1.3.8. Migraine
  - 5.1.3.9. Epilepsy
  - 5.1.3.10. Others
- 5.1.4. By Biomaterial
  - 5.1.4.1. Polymeric Biomaterials
  - 5.1.4.2. Metallic Biomaterials
  - 5.1.4.3. Ceramic Biomaterials
- 5.1.5. By End-user
  - 5.1.5.1. Hospitals
  - 5.1.5.2. Specialty Clinics
  - 5.1.5.3. Others
- 5.1.6. United States*
  - 5.1.6.1. Market Size & Forecast
    - 5.1.6.1.1. By Value
    - 5.1.6.1.2. By Volume
  - 5.1.6.2. By Type
    - 5.1.6.2.1. External Neuromodulation
      - 5.1.6.2.1.1. Transcranial Magnetic Stimulator
      - 5.1.6.2.1.2. Respiratory Electrical Stimulator
      - 5.1.6.2.1.3. Transcutaneous Electrical Nerve Stimulator
    - 5.1.6.2.2. Internal Neuromodulation
      - 5.1.6.2.2.1. Spinal Cord Stimulator
      - 5.1.6.2.2.2. Vagus Nerve Stimulator
      - 5.1.6.2.2.3. Gastric Electrical Stimulator
      - 5.1.6.2.2.4. Deep Brain Stimulator
      - 5.1.6.2.2.5. Sacral Nerve Stimulator
  - 5.1.6.3. By Application
    - 5.1.6.3.1. Parkinson's Disease
    - 5.1.6.3.2. Failed Back Syndrome
    - 5.1.6.3.3. Tremor
    - 5.1.6.3.4. Depression
    - 5.1.6.3.5. Urinary and Fecal Incontinence
    - 5.1.6.3.6. Chronic Pain Management
    - 5.1.6.3.7. Dystonia
    - 5.1.6.3.8. Migraine
    - 5.1.6.3.9. Epilepsy
    - 5.1.6.3.10. Others
  - 5.1.6.4. By Biomaterial
    - 5.1.6.4.1. Polymeric Biomaterials
    - 5.1.6.4.2. Metallic Biomaterials
    - 5.1.6.4.3. Ceramic Biomaterials
  - 5.1.6.5. By End-user
    - 5.1.6.5.1. Hospitals
    - 5.1.6.5.2. Specialty Clinics
    - 5.1.6.5.3. Others
- 5.1.7. Canada
- 5.1.8. Mexico

All segments will be provided for all regions and countries covered

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
5.4. South America
- 5.4.1. Brazil
- 5.4.2. Argentina
5.5. Middle East and Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Type
6.2. By Application
6.3. By Biomaterial
6.4. By End-user
6.5. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Medtronic PLC
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products and Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus and Geographical Presence
- 13.1.6. Recent Developments
13.2. Boston Scientific Corporation
13.3. Abbott Laboratories
13.4. Nevro Corporation
13.5. Synapse Biomedical Inc.
13.6. Nevro Corporation
13.7. Neurosigma Inc.
13.8. Neuronetics Inc.
13.9. LivaNova PLC
13.10. Neuropace Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

神経調節の世界市場の評価：タイプ別、用途別、生体材料別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Neuromodulation Market Assessment, By Type, By Application, By Biomaterial, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の神経調節市場の見通し、2017年～2031年

第5章世界の神経調節市場の見通し（地域別、2017年～2031年）

第6章市場マッピング、2023年

第7章マクロ環境と産業構造

第8章市場力学

第9章規制枠組みとイノベーション

第10章主要参入企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要参入企業の見通し

第14章戦略的提言

第15章お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Neuromodulation Market Outlook, 2017-2031F

5. Global Neuromodulation Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us and Disclaimer

神経調節の世界市場の評価：タイプ別、用途別、生体材料別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Neuromodulation Market Assessment, By Type, By Application, By Biomaterial, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の神経調節市場の見通し、2017年～2031年

第5章 世界の神経調節市場の見通し（地域別、2017年～2031年）

第6章 市場マッピング、2023年

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制枠組みとイノベーション

第10章 主要参入企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要参入企業の見通し

第14章 戦略的提言

第15章 お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Neuromodulation Market Outlook, 2017-2031F

5. Global Neuromodulation Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us and Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の神経調節市場の見通し、2017年～2031年

第5章世界の神経調節市場の見通し（地域別、2017年～2031年）

第6章市場マッピング、2023年

第7章マクロ環境と産業構造

第8章市場力学

第9章規制枠組みとイノベーション

第10章主要参入企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要参入企業の見通し

第14章戦略的提言

第15章お問い合わせと免責事項